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Summary  
Objective: Synovial fluid (SF) plays an important role in joint function. We evaluated the growth factors, insulin-like 
growth factor-1 (IGF-1) and growth hormone (GH) in SF and serum from patients with osteoarthritis (OA), rheumatoid 
arthritis (RA), gout, pseudogout and diffuse idiopathic skeletal hyperostosis (DISH). 
Design: Standard radioimmunoassay techniques were used to measure concurrent levels of IGF-1 and GH. SF samples 
and serum samples were obtained concomitantly from 27 patients with OA, 22 patients with RA, nine men with gout, 
14 pat ients with pseudogout and eight men with DISH. 
Results: In the case of IGF-1, a comparison of serum and SF levels shows that SF levels of IGF-1 are lower than 
serum levels in all groups. Men and women gave similar values. In contrast, in the case of GH, all groups, except males 
with RA, had higher GH values in SF when compared with serum values. Individual patients with other forms of 
arthritis demonstrated similar relationships. 
Conclusion: The finding that IGF-1 is present in levels about one-half as great in SF as compared with serum suggests 
that IGF-1 may be produced in lesser amounts or is utilized by the patient in customary joint function. The finding 
that GH is present in SF at values twice as high, or more, of serum levels in inflammatory arthritides uggests that 
GH may play a role in the pathophysiology of arthritic disorders. 
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In t roduct ion 
SYNOVIAL fluid (SF) p lays an impor tant  role in jo int  
funct ion,  fac i l i tat ing movement ,  and prov id ing 
jo int  nut r ients  [1]. I t  conta ins  soluble const i tuents  
such as prote ins  and e lectro lytes der ived f rom 
blood, and macromolecu les  ecreted by jo int  
t issues such as hya luron ic  acid and lubr icat ing  
glycoproteins.  SF from pat ients  with rheumato id  
arthr i t i s  (RA) and f rom pat ients  with osteo- 
ar thr i t i s  (OA) conta ins  acute  phase reactants ,  
t ransferr in ,  ceru loplasmin,  a lbumin,  ant i t ryps in ,  
acid g lycoprotein,  immunglobu l ins  G, A, M and 
beta-endorph in  [2]. SF levels of substance P, a 
pro inf lammogen,  exceed p lasma levels in RA, OA, 
and post - t raumat ic  ar thr i t i s  [3]. 
Recent ly,  we reported per turbat ions  of insul in- 
l ike growth  factor  (IGF-1) and growth  hormone 
(GH) in the serum of pat ients  with OA [4] and 
diffuse id iopathic  skeleta l  hyperostos is  (DISH) [5]. 
In pre l iminary  studies of SF, we found levels of 
Submitted 20 October 1995; accepted 5 March 1996. 
Supported by NIH grants: AR-30134 and AR20618, USPHS. 
Address correspondence and reprint requests to: Dr C. W. 
Denko, Division of Rheumatic Diseases, University Hospitals, 
11100 Euclid Avenue, Cleveland, Ohio 44106, U.S.A. 
g lucose in SF approx imated  serum levels; IGF-1 
levels were lower and GH levels exceeded those in 
serum [6]. In the present  study, we eva luated  
concomi tant  levels of the growth  factors ,  IGF-1 
and GH, in the SF and serum of pat ients  wi th  
rheumat ic  disorders.  We sought  fu r ther  ev idence 
in suppor t  of the hypothes is  that  these  growth  
factors  p lay a role in the pathophys io logy  of the 
rheumat ic  disorders.  
Pat ients  
The pat ients  were vo lunteers  recru i ted  f rom 
the Arthr i t i s  Cl inics of Un ivers i ty  Hosp i ta l s  of 
C leve land-and  Wade Park  Veterans  Adminis-  
t ra t ion  Hosp i ta l  in Cleveland, U.S.A. No pat ient  
in this group was inc luded in any  prev ious  
pub l icat ion  on b iochemica l  changes  in SF in 
rheumat ic  disorders.  The study was approved by 
the Ins t i tu t iona l  Rev iew Boards of both  insti- 
tut ions.  D iagnost ic  guidel ines were based  on the 
cr i ter ia  in 'P r imer  on the Rheumat ic  D iseases '  [7] 
for RA, systemic lupus erythematosus ,  (SLE), 
and gout. OA pat ients  met  the fo l lowing cr i ter ia:  
age over  45 years,  c l inical  symptoms of pa in  
and stiffness, jo int  swel l ing and character i s t i c  
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radiologic changes of joint space narrowing 
and osteophytes in symptomatic joints. Patients 
with DISH were older than 45 years, with clinical 
symptoms of pain and stiffness in the spine and 
characteristic radiological changes of exuberant 
osteophytes in the spine with anterolateral 
ossification and calcification of l igamentous spinal 
processes. All DISH patients studied had knee 
effusions. All patients had active disease mani- 
fested by knee effusions. Arthrocentesis was 
performed for diagnosis or for treatment. Blood 
was drawn by venipuncture shortly after joint 
fluid was obtained. Treatment programs included 
nonsteroidal nti-flammatory drugs (NSAIDs) and 
analgesic agents, corticosteroids, inhibitors of 
uric acid synthesis, immunosuppres~ants, and 
colchicine. Of 24 patients with RA, only seven 
received corticosteroids regularly in their treat- 
ment, four males and three females. Comparison 
was made with normal controls contained in 
studies previously reported from this laboratory 
[4, 5]. 
Mater ia l  and  methods  
Blood was drawn by venipuncture for assays of 
IGF-1 and GH in the serum. This was done usually 
a few minutes after SF was withdrawn from the 
knee. SF obtained from joints other than the knee 
was not included in the study. 
Blood and SF samples were treated in similar 
fashion. Blood was clotted at room temperature, 
then centrifuged and assayed. Serum glucose levels 
were determined. Blood samples were used if the 
glucose level was normal, 65-130 mg/dl. Samples 
were obtained usually between 9.30a.m. and 
12.30 p.m. 
Standard radioimmunoassays (RIA) (INCSTAR, 
Stillwater, MN, U.S.A.) were adapted for GH and 
IGF-1. The manufacturer p ovided quality control 
specimens for each peptide with each kit for each 
run; assays were validated by our laboratory. 
GH 
The GH assay is a disequilibrium RIA using 
addition of sample and guinea-pig anti-human 
serum followed by incubation. [125I]-GH is then 
added, followed by a second incubation. Preprecip- 
itated carrier, second antibody and polyethylene 
glycol (PEG) are added in a single step (INCSTAR 
manual for GH 07130). Our GH assay was adapted 
for low values by using a log-logit calculation 
mode on a programmable Beckman 5500 gamma 
counter attached to a computer which prints the 
lowest detectable dose. 
Quality control evaluation for GH RIA gave a 
coefficient of variance as follows: for low values 
<2ng/ml,  10 interkit assays 10.5%, 10 intrakit 
assays 6.8%. Cross reactivity of the human GH 
antibody was less than 0.8% for the following 
human peptides: insulin, beta-endorphin, pro- 
lactin, ACTH, placental lactogen, chorionic gon- 
adotrophin, thyroid stimulating hormone, 
luteinizing hormone, follicle stimulating hormone. 
The minimal detectable amount was 0.4 ng/ml. 
IGF-1 
The IGF-1 assay is a double antibody disequi- 
librium RIA which includes an octadecasilyl-silica 
column extractiori of serum and SF. After 
extraction, the RIA is performed by adding sample 
and rabbit anti-IGF-1 serum, followed by an 
incubation of 2 h. Then [125I] tracer is added and 
incubated for 20 h. Then the precipitating complex 
and PEG are added in one step and incubated for 
2h. (INCSTAR manual for IGF-1, catalog 
No. 53065.) Quality control studies gave the 
following results: intrakit CV, 10 assays, 8%; 
interkit CV, 10 assays 5.6%. This IGF-1 antibody 
exhibited less than 0.01% crossreactivity with 
IGF-II. Minimal detectable amount was < 2.0 nM/1. 
GLUCOSE 
Glucose was measured by the hexokinase 
method. Other hexoses such as fructose and 
mannose were detected but they were present only 
in trace amounts. Quality control evaluation gave 
the following results: 10 assays, interkit coefficient 
of variation (CV) 8%, intrakit 10 assays CV 8%. 
For evaluation of data we used a paired t-test 
comparing the SF with serum levels of each 
hormone in each patient. 
Resu l ts  
The serum and SF levels of IGF-1 and GH in 
groups of patients with RA, OA, gout, pseudogout 
and DISH are presented in Table I. A comparison 
of serum and SF levels of IGF-1 shows that the 
serum levels are higher than SF levels in all groups 
studied. GH levels, on the other hand, were 
distinctly different from the IGF-1 findings. All 
patient groups demonstrated GH levels in the SF 
to be significantly higher than the levels in the 
serum, except for male patients with RA. SF 
glucose levels were similar to serum values (data 
not shown). 
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Discuss ion  
Interrelation~s of hormones and rheumatic dis- 
orders have~ been widely studied encompassing 
natural  human rheumatic diseases and arthrit is 
induced in experimental nimals under carefully 
regulated laboratory conditions. Although the role 
of growth factors, GH and IGF-1, is not completely 
understood, it is obvious that they have more than 
the function of being generalized growth pro- 
moters. GH plays an essential role in the 
pathogenesis of acromegalic arthritis. Only when 
treatment reduces serum levels of GH to normal 
levels is there a reduction of joint pain and 
stiffness in the patient [8-10]. Several decades ago, 
Reinhart and Li [11] demonstrated hypophyseal 
GH induced an arthrit is in rats that had features 
of both OA and RA. Observations in rats and tissue 
culture experiments indicate that excessive GH 
inhibits carti lage metabolism [12, 13]. Adjuvant 
arthrit is cannot develop in rats unless there is a 
source of GH or prolactin [14], a compound with 
growth promotion similar to GH [15]. Excess GH 
occurs in women with OA [16, 17]. Patients with 
radiologic changes of OA, but without clinical 
symptoms, have normal levels of growth factors 
[18]. 
A recent report suggests that hepatocyte growth 
factor (HGF) in SF of  patients with RA is produced 
by SF cells, and is related to disease activity in RA 
[19]. This growth factor in SF from patients with 
RA was high enough to stimulate DNA synthesis 
in human hepatocytes. It is a potent mitogen for 
mature hepatocytes, and plays an essential role in 
the function of many cell types, possibly being 
involved in synovial inflammation as well. 
Another relat ion of rheumatic disorders and 
growth factors, especially GH, comes from the 
studies of Vanhagen and co-workers [20] on 
somatostatin receptor, a potent inhibitor of GH 
release. Arthrit ic clinical activity in RA and OA 
correlates with somatostatin receptor in swollen 
and painful joints. When somatostatin was 
injected into painful RA knees, symptoms im- 
proved. 
Many effects of GH are considered to be 
mediated through IGF-1, produced by the liver 
when stimulated by GH. Although IGF-1 is 
produced by many tissues [21], the liver is the main 
source [22]. IGF-1 and GH levels are influenced by 
counter-balancing mechanisms. When GH levels 
increase, thereby stimulating IGF-1 production, 
the increased IGF-1 levels, in turn, tend to suppress 
further synthesis of GH. IGF-1 thus exerts an 
anti-inflammatory effect, as well as st imulating 
growth of tissue (cartilage). IGF-1 couples with 
binding protein, and may be excessively bound in 
active stages of arthrit is disorders. 
Dore and coworkers [23] reported a single class 
Table I 
Insulin-like growth factor-1 (IGF-1) and growth hormone (GH) in synovial fluid (SF) and serum (S) of patients 
with rheumatic disorders (mean i S.D.) 
IGF-1 
Group Gender Source N (riM/l) S/SF P* GH (ng/ml) S/SF P* 
Osteoarthritis (27) Male S 12 14.9 ± 4 1.8 0.001 1.2 ± 0.5 0.6 0.002 
SF 9.4 + 4 2.4 + 1.0 
Female S 15 10.9 ± 2 1.7 0.001 1.5 + 0.1 0.6 0.001 
SF 6.4 ± 2 2.1 ± 0.8 
Rheumatoid Male S 13 20.6 ± 7 1.6 0.001 1.8 ___ 2 1.1 NS 
arthritis (24) SF 12.7 ± 4 1.6 + 0.9 
Female S 11 19.4 ± 5 1.8 0.001 1.1 ± 0.4 0.3 0.015 
SF 10.7 ± 4 3.3 ± 3 
Gout (9) Male S 9 15.7 ± 4 1.5 0.005 0.7 ± 0.3 0.4 0.013 
SF 10.7 ± 6 ~ 1.8 ± 1.6 
Pseudogout (14) Male S 7 13.7 ± 3 2.4 0.001 0.97 ± 0.2 0.6 0.019 
SF 5.6 ± 0.4 1.5 ± 0.3 
Female S 7 18.2 ± 3 1.8 0.006 0.99 + 0.5 0.4 0.007 
SF 11.0 ± 4 2.6 ± 0.3 
DISH (8) Male S 8 22.8 ± 8 2.2 0.003 0.91 ± 0.3 0.4 0.001 
SF 9.4 ± 2 2.5 + 0.6 
Normal Male S (W)t 22 22.0 ± 7 0.9 ± 0.3 
Female S (W)t 22 16.5 ± 3 1.1 ± 0.2 
S (B)t 10 22.8 ± 5 0.8 ± 0.5 
*P= paired t-test, SF vs S for each patient. 
tW = White. 
tB = Black. 
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of binding sites in human OA chondrocytes and 
normal chondrocytes. OA chondrocytes had a 
lower affinity and a higher density compared with 
normal cells. Immunohistochemical studies with 
monoclonal antibody against Type 1 IGF receptor 
showed increased staining compared with normal 
tissue. However, OA chondrocytes were unrespon- 
sive to IGF stimulation. Increased IGF binding 
protein on the cell surface may also diminish 
bioavailabil ity and reduce anabolic action. Coates 
and coworkers have reported decreased levels of 
IGF-1 (somatomedins) in diverse arthrit ides [24]. 
GH is associated with joint symptoms uch as 
pain and swelling; accordingly high levels of GH in 
a joint would appear to be undesirable. Excess 
growth-factor production by synovial ~fibroblasts 
may play an important role in inflammatory states, 
as well as influencing the formation of rheumatoid 
pannus [25, 26]. Treatment programs may benefit 
the patient by altering these hormonal imbalances. 
A common therapeutic measure in treating 
patients with RA is use of corticosteroids, agents 
that have been shown to counteract actions of GH, 
especially in regard to carti lage metabolism [27]. 
The variat ion in serum:SF ratios which we 
observed between men and women, although 
unexplained at this time, may lie in differences in 
basic physiology between men and women or 
gender variations in response to RA. Although the 
relationship of our observations to disease patho- 
genesis and pathophysiology require further study 
as to clinical implications, such studies related to 
interplays between growth factors, inflammation 
and joint tissue responses will hopefully provide 
clues not only to mechanisms but to new 
therapeutic approaches. In this regard, further 
assessment of the symptoms of absolute amounts 
of specific hormones in SF, irrespective of serum: 
SF ratios would be of interest. 
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